Abeona Therapeutics (ABEO) Stock
Biotech company developing gene therapies for rare diseases. Here's the price, business snapshot, and what's worth knowing about Abeona Therapeutics in August 2026.
Abeona Therapeutics Inc. (ABEO) is a clinical-stage biotechnology company focused on developing gene and cell therapies for rare genetic diseases. With a market capitalisation of about $280.49 million, Abeona operates in a high-risk, high-reward segment where clinical progress, regulatory decisions and partnership deals can materially affect value. Investors should know that outcomes in this sector are often binary — positive trial data or approvals can drive significant upside, while setbacks, delays or financing needs can weigh heavily on the share price. Development timelines are typically long and capital intensive. This summary is educational only and not personalised investment advice; consider your risk tolerance, investment horizon and the possibility of losing capital before taking action. Conduct further due diligence on Abeona’s pipeline, trial results, financial position and regulatory environment, and consult a regulated financial adviser for tailored guidance.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Abeona Therapeutics' stock with a target price of $20.64, indicating significant growth potential.
Financial Health
Abeona Therapeutics is generating some cash flow and revenue, but overall performance is mixed.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Ahead
Progress in trials or regulatory news can sharply re-rate the stock, though clinical setbacks are common and can quickly reverse gains.
Small-cap Volatility
With a market cap near $280M, Abeona can show large price swings; potential returns come with higher risk and financing sensitivity.
Rare Disease Focus
Targeting rare genetic disorders means high unmet medical need and potential partner interest, but patient populations are small and outcomes uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
